| Today’s Big NewsDec 2, 2024 |
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| By Nick Paul Taylor Novartis is paying $1 billion up front for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program. |
|
|
|
By Conor Hale The company’s wearable therapy improved overall survival as part of a first-line regimen for patients with inoperable pancreatic adenocarcinoma, one of the most lethal cancers. |
By Fraiser Kansteiner Sanofi is laying out roughly 1 billion euros ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone. The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to beef up local end-to-end insulin production. |
By Ben Adams Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with megablockbuster sales in a market that could be worth $126 billion by 2030 just on the horizon. |
|
The right funding at the right time is crucial for life sciences companies that want to fuel innovation and scale operations. Download this free whitepaper to drive innovation, expand operations and lead your organization to further success.
|
|
By Fraiser Kansteiner The General Court of the European Union decided not to extend a suspension of the European Commission’s decision to revoke Ocaliva’s marketing authorization. In turn, Intercept's liver disease drug, which is marketed by Advanz Pharma overseas, has lost its EU approval. |
By Gabrielle Masson Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 million every year. |
By Conor Hale GE HealthCare unveiled a new mammography system with AI features aimed at easing the pressures from a shortage of trained technologists. |
By Nick Paul Taylor The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response letter cited “deficiencies in the clinical application” but it plans to reapply or appeal. |
By Kevin Dunleavy The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer. |
By Zoey Becker Along with the company's new data drop at the European Society for Medical Oncology Asia Congress, Merus also secured a partner for a separate candidate that's in line for an upcoming FDA decision. |
By Nick Paul Taylor GSK has brought its message about the risks of antimicrobial resistance to commuters in London. The drugmaker worked with its partner the Fleming Initiative to tell people traveling through Paddington Station about the rise of AMR. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
